Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients

Summary

The goals of this study are to evaluate the efficacy of JNJ-18038683 in an 8 week trial to ameliorate the cognitive deficit and reduce residual depressive symptoms in 60 stable bipolar outpatients receiving treatment for depression. JNJ-18038683 will be studied and compared with placebo as adjunctive treatment to standard pharmacologic treatment for bipolar disorder.

Timeline

Start

2015-09

Primary completion

2021-09

Completion

2022-12

Publications

• Arshadi M, Elmaadawi AZ, Nasr S, Jayathilake K, Rassnick S, Ford L, Drevets WC, Meltzer HY. Lack of Efficacy of JNJ-18038683 on Cognitive Impairment in Patients With Stable Bipolar Disorder. J Clin Psychopharmacol. 2024 Sep-Oct 01;44(5):481-491. doi: 10.1097/JCP.0000000000001889.

Drugs

Indications